Supporting Information

Janus Particles Self-Assembled by Small Organic Molecules Based on Atypical Asymmetric Gemini Surfactant Design

Lei Tang*,† Jun Yang,† Qinqin Yin,† Linghui Yang,† Deying Gong,† Feng Qin,‡ Junyang Liu,‡ Qin Fan,‡ Jiahong Li,§ Wenling Zhao,† Weiyi Zhang,† Jiyu Wang,§ Tao Zhu,† Wensheng Zhang*,† and Jin Liu*,†

†Laboratory of Anaesthesia & Critical Care Medicine, Translational Neuroscience Center, and Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.

‡West China Hospital, Sichuan University, Chengdu 610041, P.R. China.

§Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu 610041, P.R. China.

Corresponding Author

*E-mail: manstein_1984@sina.com;

*E-mail: zhang_ws@scu.edu.cn.

*E-mail: scujinliu@gmail.com.

Claim:
The animal experiments were performed in accordance with the guide for the care and use of medical laboratory animals (Ministry of Health, China). All animal procedures in this work were approved by the Institutional Animal Experimental Ethics Committee of Sichuan University (Chengdu, China, 13 Approval file No. 2015014A).
Table of Contents

SI.1 Synthesis and structure information .................................................. P1
SI.2 CMC determination of compound 3, 8 and 9 ........................................ P30
SI.3 EC$_{50}$ determination of compound 3 and 8 ....................................... P30
SI.4 TEM observations with phosphotungstic acid .................................... P33
SI.5 TEM observations with other stain agents ......................................... P36
SI.6 DLS measurements ............................................................................ P37
SI.7 Cryo-TEM observations ..................................................................... P38
SI.8 Determination of onset time .............................................................. P39
Reference ................................................................................................. P40

SI.1 Synthesis and structure information

![Synthesis reaction](image)

**Synthesis of 2-(2,6-dimethylphenylamino)-N,N-diethyl-N-(2-hydroxyethyl)-2-oxo-ethanaminium bromide (13)**

2-bromoethanol 53.2g (426mmol) and lidocaine 100g (426mmol) were added in a flask, sealed. The mixture was heated at 100°C for 8 hours. The reaction residual was cooled into room temperature, and mixed with ethyl acetate 100 ml with vigorous stirring. The white solid in the suspension was filtered, and washed with ethyl acetate (100mL x 3). The white solid was dried under reduced pressure, and obtained 124.4g product 13 as white solid, yield 81.2%. Melt point: 185.5~186.4°C. $^1$H NMR (400MHz, CD$_3$OD) $\delta$ : 7.11~7.16 (m, 3H), 4.50~4.51 (m, 2H), 4.05~4.07 (m, 2H), 3.75~3.87 (m, 6H), 2.26 (s, 6H), 1.43 (t, $J = 7.2$Hz, 6H). $^{13}$C NMR (100 MHz, CD$_3$OD) $\delta$ : 8.28, 18.65, 56.81, 56.93, 58.48, 61.63, 128.92, 129.31, 134.19, 136.80, 164.15. HRMS: [C$_{16}$H$_{27}$N$_2$O$_2$]$^+$, 279.2079, found 279.2075.
General method on synthesis of product 3~6

To the mixture of 13 (6.0g, 16.7mmol), triphosgene (2.47g, 8.34mmol) and 1,2-dichloroethane (100ml), pyridine (1.4g, 17.6mmol) in 1,2-dichloroethane (100ml) were added dropwise at room temperature for 20min. After addition, this mixture was allowed to stirring at room temperature for 3h. Then the fatty alcohol (16.7mmol) in 1,2-dichloroethane (30ml) was added. This solution was stirred for another 16h at 50℃, and cooled to room temperature.

Saturated brine (200ml) was poured into the reaction flask. The organic layer was washed with saturated brine (200mL x 6). The organic solvent was removed in vacuo. The residue was further purified by chromatography with CH₂Cl₂-CH₃OH as eluent to give product as white powder.

Characterization data of compounds 3

2-(2,6-dimethylphenylamino)-N,N-diethyl-N-(2-(heptyloxycarbonyloxy)ethyl)-2-oxoethanamminium chloride (3). Obtained as white powder, yield: 43%. Melting Point: 137.7~138.3℃. ¹H NMR (400 MHz, CDCl₃) δ : 10.34 (s, 1H), 7.00~7.08 (m, 3H), 5.00 (m, 2H), 4.64 (br, 2H), 4.16 (t, J = 6.8 Hz, 2H), 4.04 (m, 2H), 3.66~3.76 (m, 4H), 2.24 (s, 6H), 1.60~1.63 (m, 2H), 1.54~1.56 (m, 8H), 0.86 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 8.33, 14.06, 14.19, 18.82, 21.06, 22.54, 25.53, 26.89, 28.48, 28.81, 31.64, 36.40, 56.40, 57.56, 57.82, 60.39, 60.59, 69.33, 76.79, 127.42, 128.12, 133.11, 135.04, 154.31, 161.77. HRMS: [C₂₆H₄₁N₂O₄]⁺: 421.3107, found: 421.3070. Content of Cl⁻ by IC: 99.1%. Content by HPLC (UV detector, 220nm, Zorbex 300SB-C3, 20mmol/L NH₄Ac-H₂O : CH₃CN, 90% for 0~10min and 10% for 10~30min, 1.5ml/min): 100%. (See Fig.S1).
Figure S1: $^1$H NMR, $^{13}$C NMR, HRMS and HPLC of compound 3
Characterization data of compounds 4

\[
\text{2-(2,6-dimethylphenylamino)-N,N-diethyl-2-oxo-} \text{N-(2-(pentyloxy carbonyloxy)ethyl) ethanaminium chloride (4).} \]

Obtained as white powder, yield: 39%.

Melting Point: 88.1–90.2 °C. \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\): 11.01 (s, 1H), 7.02–7.09 (m, 3H), 5.00 (br, 2H), 4.66 (br, 2H), 4.14 (t, \(J = 6.8\) Hz, 2H), 4.05 (m, 2H), 3.68–3.74 (m, 4H), 2.26 (s, 6H), 1.65 (t, \(J = 6.8\) Hz, 2H), 1.49 (t, \(J = 7.2\) Hz, 6H), 1.34–1.32 (m, 4H), 0.91 (t, \(J = 7.2\) Hz, 3H). \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \(\delta\): 8.33, 13.90, 18.80, 22.21, 25.53, 27.68, 28.16, 56.40, 57.55, 57.94, 60.60, 69.16, 127.41, 128.11, 133.11, 135.06, 154.32, 161.80. HRMS: [C\(_{22}\)H\(_{41}\)N\(_2\)O\(_4\)]\(^+\): 393.2753, found: 393.2646. Content of Cl\(^-\): 98.7%. Content by HPLC (UV detector, 220nm, Zorbex 300SB-C3, 20mmol/L NH\(_4\)Ac-H\(_2\)O : CH\(_3\)CN, 90% for 0~10min and 10% for 10~30min, 1.5ml/min): 97.4%. (See Fig.S4).
Characterization data of compounds 5

\[
\text{2-(2,6-dimethylphenylamino)-N,N-diethyl-N-(2-}
\text{(nonyloxy carbonyloxy)ethyl)-2-oxoethanaminium}
\]
\[
\text{chloridemp (5). Obtained as white powder, yield: 41\%.
Melting Point: 92.7–94.3}^\circ\text{C. }^1\text{H NMR (400 MHz, CDCl}_3\text{)} \delta:
\]
\[
10.47 (\text{br, 1H}), 7.03–7.11 (\text{m, 3H}), 5.08 (\text{s, 2H}), 4.66–4.69 (\text{m, 2H}), 4.15 (\text{t, } J = 6.7 \text{ Hz, 2H}), 4.04–4.11 (\text{m, 2H}), 3.67–3.83 (\text{m, 4H}), 2.28 (\text{br, 6H}), 1.99 (\text{br, 2H}), 1.63–1.70 (\text{m, 2H}), 1.54 (\text{t, } J = 7.2 \text{ Hz, 6H}), 1.30–1.37 (\text{m, 4H}), 0.90 (\text{t, } J = 4.0 \text{ Hz, 3H}). \]
\[\text{^13}\text{C NMR (100 MHz, CDCl}_3\text{)} \delta: 8.50, 13.92, 18.92, 18.94, 22.24, 27.69, 28.18, 56.57, 57.85, 60.54, 69.30, 127.62, 128.19, 132.80, 135.11, 154.30, 161.75. \]
HRMS: [C\text{\textsubscript{26}H\textsubscript{45}N\textsubscript{2}O\textsubscript{4}}]\text{\textsuperscript{+}}, 449.3379, found: 449.3387. Content of Cl\textsuperscript{-} by IC: 99.3\%. Content by HPLC (UV detector, 220nm, Zorbex 300SB-C3, 20mmol/L NH\textsubscript{4}Ac-H\textsubscript{2}O : CH\textsubscript{3}CN, 90\% for 0–10min and 10\% for 10–30min, 1.5ml/min): 100\% (See Fig.S3).
Figure S3: $^1$H NMR, $^{13}$C NMR, HRMS and HPLC of compound 4

Characterization data of compounds 6

2-(2,6-dimethylphenylamino)-N-(2-(dodecyloxycarbonyloxy)ethyl)-N,N-diethyl-2-oxoethanaminium chloride (6). Obtained as white powder, yield: 45%. Melting Point: 102.2–103.0°C. $^1$H NMR (400 MHz,
CDCl$_3$ $\delta$: 10.52 (br, 1H), 7.03~7.11 (m, 3H), 5.08 (s, 2H), 4.67 (t, $J = 4.6$ Hz, 2H), 4.14 (t, $J = 6.8$ Hz, 2H), 4.04~4.06 (m, 4H), 2.28 (s, 6H), 2.03 (br, 2H), 1.67 (t, $J = 6.8$ Hz, 2H), 1.53 (t, $J = 7.2$ Hz, 6H), 1.26~1.30 (m, 18H), 0.88 (t, $J = 6.8$ Hz, 3H).

$^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$: 8.49, 14.14, 18.92, 22.70, 28.50, 29.19, 29.35, 29.49, 29.58, 29.64, 31.92, 56.57, 57.82, 57.87, 60.54, 69.32, 127.60, 128.18, 132.83, 135.11, 154.30, 161.76. HRMS: [C$_{29}$H$_{51}$N$_2$O$_4$]$^+$, 491.3638, found: 491.3642. Content of Cl$^-$ by IC: 99.1%. Content by HPLC (UV detector, 220nm, Zorbex 300SB-C3, 20mmol/L NH$_4$Ac-H$_2$O: CH$_3$CN, 90% for 0~10min and 10% for 10~30min, 1.5ml/min): 100%. (See Fig.S4).
Synthesis of N-(2-(2,6-dimethylphenylamino)-2-oxoethyl)-N,N-diethyl-3-hydroxy propan-1-aminium chloride (14)

3-bromopropan-1-ol 5.9g (42.7mmol) and lidocaine 10g (42.7mmol) were added in a flask. The mixture was heated at 110℃ for 8 hours. The reaction residual was cooled into room temperature, and mixed with ethyl acetate 100 ml with vigorous stirring. The white solid in the suspension was filtered, and washed with ethyl acetate (100mL x 3). The white solid was dried under reduced pressure, and obtained 13.8g product 14 as white solid, yield 80.3%. Melting Point: 182.0~183.2℃. 1H NMR (400 MHz, CD3OD) δ : 7.12~7.19 (m, 3H), 4.44 (s, 2H), 3.67~3.74 (m, 8H), 2.27 (s, 6H), 2.07~2.00 (m, 2H), 1.44 (t, J = 7.2 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ : 8.32, 18.65, 18.74, 26.35, 56.54, 57.72, 58.37, 59.34, 129.01, 129.36, 134.16, 136.75, 136.70. HRMS: [C17H29N2O2]+: 293.2224, found: 293.2224.
Figure S5: $^1$H NMR and $^{13}$C NMR of compound 12
Synthesis of N-(2-(2,6-dimethylphenylamino)-2-oxoethyl)-N,N-diethyl-3-(heptyloxycarbonyloxy)propan-1-aminium chloride (7)

To the mixture of heptan-1-ol 1.94g (16.7mmol) triphosgene (2.47g, 8.34mmol) and 1,2-dichloroethane (30ml), pyridine (1.4g, 17.6mmol) in 1,2-dichloroethane (20ml) were added dropwise at room temperature for 20min. After addition, this mixture was allowed to stirring at 50°C for 3h. Then the mixture was added dropwise to 12 (5.5g, 16.7mmol) in 1,2-dichloroethane (200ml). This solution was stirred for another 16h at 50°C, and cooled to room temperature.

Saturated brine (200ml) was poured into the reaction flask. The organic layer was washed with saturated brine (200mL x 6). The organic solvent was removed in vacuo. The residue was further purified by chromatography with CH$_2$Cl$_2$-CH$_3$OH as eluent to give product (7) as white syrupy solid, yield: 26%. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$: 11.03 (s, 1H), 7.03~7.10 (m, 3H), 4.95 (s, 2H), 4.26 (t, $J$ = 5.6 Hz, 2H), 4.13 (t, $J$ = 6.8 Hz, 2H), 3.64~3.77 (m, 6H), 2.30~2.36 (m, 2H), 2.27 (s, 6H), 1.62~1.67 (m, 2H), 1.50 (t, $J$ = 7.2 Hz, 6H), 1.25~1.34 (m, 8H), 0.89 (t, $J$ = 6.8 Hz, 3H). $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$: 8.12, 14.04 18.78, 22.27, 22.54, 25.58, 28.55, 28.83, 31.64, 55.43, 56.70, 57.04, 64.07, 70.21, 127.39, 128.11, 133.12, 135.03, 154.77, 161.80. HRMS: [C$_{25}$H$_{43}$N$_2$O$_4$]$^+$: 435.3217, found: 435.3218. Content of Cl$^-$ by IC: 99.1%.
Synthesis of 2-(2,6-dimethylphenylamino)-N,N-diethyl-N-(2-(nonanoyloxy)ethyl)-2-oxoethanaminium chloride (8)

Nonanoic acid 2.6g (16.7mmol) and CH$_2$Cl$_2$ 10mL were added in a dry flask. The solution of oxalyl chloride 1.3g (10.2mmol) in CH$_2$Cl$_2$ 10mL were added dropwise at room temperature during 10min. The mixture was stirred for 20min, and added dropwise into a mixture of 13 (6g, 16.7mmol), pyridine (2.0g, 25.0mmol) and CH$_2$Cl$_2$ 30mL in a new flask at room temperature. After the reaction mixture was stirred at 40°C for 12 hours, saturated brine (200ml) was poured into the flask. The organic layer was washed with saturated brine (200mL x 6). The organic solvent was removed in vacuo. The residue was further purified by chromatography (CH$_2$Cl$_2$ : CH$_3$OH = 20 : 1) to obtained product 8 (2.8g) as white powder, yield: 37%. Melting Point: 121.5~123.5°C. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$: 11.02 (s, 1H), 7.02~7.10 (m, 3H), 5.04 (s, 2H), 4.62 (t, $J$ = 4.8 Hz, 2H), 3.99 (t, $J$ = 4.8 Hz, 2H), 3.71~3.77 (m, 2H), 2.33 (t, $J$ = 7.6 Hz, 2H), 2.27 (s, 6H), 1.58~1.61 (m, 2H), 1.51 (t, $J$ = 6.8 Hz, 6H),
1.30 (br, 10H), 0.88 (t, J = 6.8 Hz, 3H). $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ : 8.35, 14.09, 18.82, 22.62, 24.61, 29.07, 29.17, 31.77, 33.93, 56.30, 57.16, 57.48, 57.65, 127.44, 128.14, 133.06, 135.10, 161.85, 172.92. HRMS: [C$_{25}$H$_{43}$N$_2$O$_3$]$^+$: 419.3268, found: 419.3268. Content of Cl$^{-}$: 99.2%.
Synthesis of N-(2-(2,6-dimethylphenylamino)-2-oxoethyl)-N,N-diethyldodecan-1-aminium chloride (9)

Lidocaine 5g (21.3mmol) and 1-bromododecane 10.6g (42.6mmol) were added in a flask. The mixture was heated at 100℃ for 24 hours. The reaction residual was cooled into room temperature, and mixed with ethyl acetate 100 ml with vigorous stirring. The white solid in the suspension was filtered, and washed with ethyl acetate (100mL x 3). The white solid was dried under reduced pressure, and obtained product 9 (4.0g) as white powder, yield: 47%. Melting Point: 112.5~113.8℃. \[^1^H\text{NMR (400 MHz, CDCl}_3\text{)} \delta : 11.14 (s, 1H), 7.02~7.09 (m, 3H), 4.86 (s, 2H), 3.66 (t, J = 6.8 Hz, 4H), 3.58~3.64 (m, 2H), 3.64~3.77 (m, 6H), 2.27 (s, 6H), 1.80 (br, 2H), 1.47 (t, J = 7.2 Hz, 6H), 1.25~1.34 (m, 18H), 0.88 (t, J = 7.2 Hz, 3H). \[^{13}\text{C NMR (100 MHz, CDCl}_3\text{)} \delta : 8.25, 14.11, 18.83, 22.21, 22.66, 26.41, 29.02, 29.29, 29.38, 29.54, 29.55, 31.87, 55.24, 56.99, 59.46, 127.35, 128.10, 133.20, 135.00, 161.84. HRMS: [C\textsubscript{26}H\textsubscript{47}N\textsubscript{2}O\textsuperscript{+}]^+: 403.3683, found: 403.3682. Content of Cl\textsuperscript{-} by IC: 98.3%.}
Synthesis of 2-(2,6-dimethylphenylamino)-N,N-diethyl-N-(2-(heptyloxy)ethyl)-2-oxoethanaminium chloride (10)

Heptan-1-ol 3.7g (32.0mmol), 2-bromoethanol 4.0g (32.0mmol) and sulfuric acid (98%) 3.2g (32.0mmol) were added in a flask, and heated at 150℃ for 2 hours. After cooled into room temperature, the mixture was poured into cooled water 200mL, and extracted with CH₂Cl₂ (30mL x 3).

The organic layer dried with anhydrous sodium sulfate, and added into another flask together with lidocaine 5g (21.3mmol). After the solvent was removed in vacuo, the residual was stirred at 110℃ for 8 hours. Saturated brine (200ml) was poured into the flask. The organic layer was washed with saturated brine (200mL x 6). The organic solvent was removed in vacuo. The residue was further purified by chromatography (CH₂Cl₂ : CH₃OH = 20 : 1) to obtained product 10 (0.89g) as colourless syrupy, yield: 10.1%. ¹H NMR (400 MHz, CDCl₃ : CF₃COOD = 50 : 1) δ : 7.13~7.16 (m, 1H), 7.06~7.08 (m, 2H), 4.70 (s, 1.5H), 4.58 (s, 0.5H), 3.63~3.88 (m, 7H), 3.48 (t, J = 3.2 Hz, 2H), 2.19 (s, 6H), 1.62~1.67 (m, 2H), 1.58 (t, J = 6.8 Hz, 2H), 1.42~1.47 (m, 6H), 1.26~1.28 (m, 8H), 0.88 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 8.40, 14.06, 18.76, 22.41, 26.04, 29.02, 29.42, 31.73,
55.08, 56.28, 57.22, 58.79, 64.26, 71.98, 127.40, 128.11, 133.12, 135.12, 162.17.
HRMS: [C\textsubscript{23}H\textsubscript{41}N\textsubscript{2}O\textsubscript{2}]\textsuperscript{+}: 377.3163, found: 377.3157. Content of Cl\textsuperscript{-} by IC: 99.3%.
Synthesis of 2-(diethylamino)-N-(2,6-dimethylphenyl)-N-methylacetamide hydrochloride (15)

\[
\text{a). NaH, THF} \quad b). \text{CH}_3l \quad c). \text{HCl}
\]

Figure S9: $^1$H NMR, $^{13}$C NMR and HRMS of compound 10
To a dry flask, lidocaine 10g (42.7mmol) and anhydrous THF 50mL were added under argon. NaH (60%) 1.7g (42.7mmol) was then added at -5°C during 5min. Iodomethane 6.4g (45mmol) in anhydrous THF 20mL was added dropwise during 20min, and stirred at -5°C for 2 hours.

Hydrochloric acid (0.1N) 300mL was added into the reaction solution, and extracted with CH₂Cl₂ (50mL x 3). The organic layer was washed with saturated brine (200mL) and removed in vacuo. The residue was further purified by chromatography (CH₂Cl₂ : CH₃OH = 50 : 1) to obtained product 15 (11.9g) light yellow oil, yield: 61%.

¹H NMR (400 MHz, CDCl₃) δ : 7.07~7.19 (m, 3H), 3.13 (s, 3H), 2.91 (s, 2H), 2.68 (q, J = 7.2 Hz, 4H), 0.98 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 11.66, 17.61, 29.66, 34.40, 47.56, 53.26, 128.33, 129.07, 135.56, 140.20, 169.88. HRMS: [C₁₅H₂₅N₂O]⁺: 249.1961, found: 249.1961.
Synthesis of 2-((2,6-dimethylphenyl)(methyl)amino)-N,N-diethyl-N-(2-(heptyloxy carbonyloxy)ethyl)-2-oxoethanaminium chloride (11)

Compound 15 10.0g (37.1mmol) was dissolved in CH$_2$Cl$_2$ 100mL, washed with solution of Na$_2$CO$_3$ (1N, 50mL x 2). The organic layer was dried by anhydrous sodium sulfate, filtered, and removed in vacuo.

The residue and 2-bromoethanol 4.6g (37.1mmol) were added in a flask. The mixture was heated at 100°C for 8 hours. The reaction residual was cooled into room temperature, and mixed with ethyl acetate 100 ml with vigorous stirring. The white solid in the suspension was filtered, and washed with ethyl acetate (100mL x 3). The white solid was dried under reduced pressure.

The white solid was then mixed with triphosgene (2.47g, 8.34mmol) and 1,2-dichloroethane (100ml) in a flask. Pyridine (1.4g, 17.6mmol) in 1,2-dichloroethane
(100ml) were added dropwise at room temperature for 20min. After addition, this mixture was allowed to stirring at room temperature for 3h. Then the heptan-1-ol 1.94g (16.7mmol) in 1,2-dichloroethane (30ml) was added. This solution was stirred for another 16h at 50°C, and cooled to room temperature.

Saturated brine (200ml) was poured into the reaction flask. The organic layer was washed with saturated brine (200mL x 6). The organic solvent was removed in vacuo. The residue was further purified by chromatography with CH$_2$Cl$_2$-CH$_3$OH as eluent to give product (11) 5.8g as colourless syrupy, yield: 33%. $^1$H NMR (400 MHz, CDCl$_3$ : CF$_3$COOD = 50 : 1) $\delta$: 7.29~7.11 (m, 3H), 5.37 (s, 0.5H), 4.57 (H$_a$, 2H), 4.18 (t, $J = 6.8$ Hz, 2H), 4.07 (H$_b$, 2H), 3.66~3.76 (m, 4.5H), 3.36 (s, 0.5H), 3.12 (s, 2H), 2.25 (s, 5H), 2.16 (s, 1H), 1.71~1.64 (m, 2H), 1.27~1.44 (m, 14H), 0.88 (t, $J = 4.4$ Hz, 3H). $^{13}$C NMR (100 MHz, CDCl$_3$ : CF$_3$COOD = 50 : 1) $\delta$: 7.54, 13.92, 17.24, 22.48, 28.40, 28.76, 31.59, 35.62, 37.03, 55.85, 56.36, 57.61, 60.50, 69.74, 129.20, 130.12, 130.16, 134.19, 134.78, 136.76, 154.60(d, $J = 9.9$ Hz), 163.60, 164.24. HRMS: [C$_{25}$H$_{43}$N$_2$O$_4$]$^+$: 435.3217, found: 435.3220. Content of Cl$^-$ by IC: 98.8%.
Synthesis of 2-bromo-N-cyclohexylacetamide (16)

Cyclohexanamine 5g (50mmol) and triethylamine 6.1g (60mmol) were dissolved by CH₂Cl₂ 100mL in a dry flask. 2-bromoacetyl bromide 10.1g (50mmol) in CH₂Cl₂ 50mL was added dropwise at room temperature for 20min. After addition, this mixture was allowed to stirring at room temperature for 3h.

The reaction solution was poured into solution of Na₂CO₃ (1N) 300mL. The organic layer was separated, dried by anhydrous sodium sulfate, filtered. The organic solvent was removed in vacuo, and the residue was recrystallized (cyclohexane : ethyl acetate = 5 : 1) to give product (16) 16.7g as white powder, yield: 77%. Melting Point: 105.8~107.5˚C. ¹H NMR (400 MHz, CDCl₃) δ : 6.45 (br, 1H), 4.03 (s, 2H), 3.74~3.84 (m, 1H), 1.91~1.95 (m, 2H), 1.71~1.96 (m, 2H), 1.61~1.66 (m, 1H), 1.40~1.44 (m, 2H), 1.25~ 1.39 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 24.71, 25.40, 32.78, 42.73, 48.65, 164.84. HRMS: [C₈H₁₅ClNO]+: 176.0837, found: 176.0834.
Figure S12: $^1$H NMR and $^{13}$C NMR of compound 14
Synthesis of 2-(cyclohexylamino)-N,N-diethyl-N-(2-(heptyloxycarbonyloxy)ethyl)-2-oxoethanaminium chloride (12)

2-bromo-N-cyclohexylacetamide (16) 10g (45.4mmol) and 2-(diethylamino)ethanol 5.3g (45.4mmol) were added in a flask, and heated at 110°C for 8h.

After cooling to room temperature, the residue was mixed with triphosgene (6.7g, 22.7mmol) and 1,2-dichloroethane (100ml) in a flask. Pyridine (3.6g, 45.4mmol) in 1,2-dichloroethane (100ml) were added dropwise at room temperature for 20min. After addition, this mixture was allowed to stirring at room temperature for 3h. Then the heptan-1-ol 1.94g (16.7mmol) in 1,2-dichloroethane (30ml) was added. This solution was stirred for another 24h at 50°C, and cooled to room temperature.

Saturated brine (200ml) was poured into the reaction flask. The organic layer was washed with saturated brine (200mL x 6). The organic solvent was removed in vacuo. The residue was further purified by chromatography with CH₂Cl₂-CH₃OH as eluent to give product (12) 7.5g as colourless syrupy, yield: 38%. ¹H NMR (400 MHz, CDCl₃) δ : 9.58 (d, J = 7.6 Hz , 1H), 4.66 (t, J = 4.8 Hz, 2H), 4.62 (br, 2H), 4.16 (t, J = 6.8 Hz, 2H), 3.96~3.98 (m, 2H), 3.59~3.75 (m, 5H), 1.84~1.88 (m, 2H), 1.75~1.79 (m, 2H), 1.63~1.68 (m, 2H), 1.58~1.59 (m, 1H), 1.48 (t, J = 7.2 Hz, 6H), 1.20~1.45 (m, 13H), 0.88 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 8.35, 14.05 22.55, 24.79, 25.27, 25.55, 28.50, 28.82, 31.64, 32.09, 49.24, 56.61, 57.90, 58.11, 60.54, 69.28, 154.32, 161.70. HRMS: [C₂₂H₄₃N₂O₄]+: 399.3217, found: 3993.219. Content of Cl⁻ by IC: 99.3%.
Figure S13: $^1$H NMR, $^{13}$C NMR and HRMS of compound 12

SI.2 CMC determination of compound 3, 8 and 9

Table S1 Surface tension determination of compound 3

<table>
<thead>
<tr>
<th>Concentration (mmol/L)</th>
<th>Surface tension (mN/m)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Run 1</td>
</tr>
<tr>
<td>56</td>
<td>30.1</td>
</tr>
<tr>
<td>28</td>
<td>33.2</td>
</tr>
<tr>
<td>14</td>
<td>32.7</td>
</tr>
<tr>
<td>7</td>
<td>31.6</td>
</tr>
<tr>
<td>3.5</td>
<td>32.5</td>
</tr>
<tr>
<td>1.8</td>
<td>34.3</td>
</tr>
<tr>
<td>0.88</td>
<td>38.2</td>
</tr>
<tr>
<td>0.44</td>
<td>43.6</td>
</tr>
</tbody>
</table>
$B1 \ (\gamma_{CMC}) = 32.5, \ CMC = 2.51\text{mmol/L}$

Figure S14  CMC of compound 3 calculated by surface tension

Table S2 Surface tension determination of compound 8

<table>
<thead>
<tr>
<th>Concentration (mmol/L)</th>
<th>Surface tension (mN/m)</th>
<th>Run 1</th>
<th>Run 2</th>
<th>Run 3</th>
<th>Run 4</th>
<th>Run 5</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>56</td>
<td></td>
<td>28.5</td>
<td>28.4</td>
<td>28.2</td>
<td>27.9</td>
<td>30.0</td>
<td>28.2</td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>24.3</td>
<td>23.8</td>
<td>23.9</td>
<td>24.9</td>
<td>23.5</td>
<td>24.1</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>23.3</td>
<td>23.5</td>
<td>23.2</td>
<td>22.9</td>
<td>22.9</td>
<td>23.2</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>21.0</td>
<td>21.2</td>
<td>20.4</td>
<td>20.4</td>
<td>20.5</td>
<td>20.7</td>
</tr>
<tr>
<td>3.5</td>
<td></td>
<td>21.5</td>
<td>21.5</td>
<td>22.0</td>
<td>21.9</td>
<td>22.4</td>
<td>21.9</td>
</tr>
<tr>
<td>1.8</td>
<td></td>
<td>23.7</td>
<td>24.2</td>
<td>23.0</td>
<td>22.3</td>
<td>22.1</td>
<td>23.1</td>
</tr>
<tr>
<td>0.88</td>
<td></td>
<td>22.4</td>
<td>23.0</td>
<td>23.0</td>
<td>23.3</td>
<td>23.2</td>
<td>23.0</td>
</tr>
<tr>
<td>0.44</td>
<td></td>
<td>31.0</td>
<td>30.8</td>
<td>30.0</td>
<td>30.3</td>
<td>29.6</td>
<td>30.3</td>
</tr>
<tr>
<td>0.22</td>
<td></td>
<td>35.6</td>
<td>36.6</td>
<td>34.3</td>
<td>34.2</td>
<td>33.4</td>
<td>34.8</td>
</tr>
</tbody>
</table>
0.11  39.4  41.6  41.4  41.8  41.1  41.1
0.056  44.2  44.2  44.4  43.8  43.7  44.1
0.028  44.4  48.3  48.2  47.2  48.2  47.3

B1 (γ_{CMC}) = 22.4, CMC = 1.27mmol/L

Figure S15  CMC of compound 6 calculated by surface tension

Table S3 Surface tension determination of compound 9

<table>
<thead>
<tr>
<th>Concentration (mmol/L)</th>
<th>Run 1</th>
<th>Run 2</th>
<th>Run 3</th>
<th>Run 4</th>
<th>Run 5</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>23.7</td>
<td>26.1</td>
<td>26.2</td>
<td>26.2</td>
<td>26.2</td>
<td>26.2</td>
</tr>
<tr>
<td>14</td>
<td>24.3</td>
<td>25.8</td>
<td>25.6</td>
<td>25.4</td>
<td>24.8</td>
<td>25.4</td>
</tr>
<tr>
<td>7</td>
<td>24.6</td>
<td>26.0</td>
<td>25.7</td>
<td>25.6</td>
<td>25.1</td>
<td>25.4</td>
</tr>
<tr>
<td>3.5</td>
<td>24.8</td>
<td>25.7</td>
<td>25.1</td>
<td>25.0</td>
<td>25.1</td>
<td>25.1</td>
</tr>
<tr>
<td>1.8</td>
<td>25.3</td>
<td>24.6</td>
<td>24.0</td>
<td>24.1</td>
<td>23.7</td>
<td>24.5</td>
</tr>
<tr>
<td>0.88</td>
<td>23.0</td>
<td>19.6</td>
<td>20.0</td>
<td>20.6</td>
<td>23.9</td>
<td>23.4</td>
</tr>
<tr>
<td>0.44</td>
<td>32.7</td>
<td>33.9</td>
<td>35.3</td>
<td>33.6</td>
<td>32.0</td>
<td>33.0</td>
</tr>
<tr>
<td>0.22</td>
<td>39.0</td>
<td>38.9</td>
<td>36.8</td>
<td>37.3</td>
<td>38.2</td>
<td>37.4</td>
</tr>
</tbody>
</table>
The surface tension of compound 3, 8 and 9 in different concentrations at 25°C in pure water was detected respectively. The CMC was calculated by that data.\textsuperscript{S1}

**SI.3 EC\textsubscript{50} determination of compound 3 and 8**

\textit{EC}\textsubscript{50} of compound 3 and 8 was measured by “up-and-down” method.\textsuperscript{S2} Effective sciatic nerve blockade that lasted for more than 30min was defined as positive response, otherwise negative response. When a positive response was developed after a given dose, the next concentration that was 1.2 times lower than the last one was administrated. If a negative response was resulted, the next concentration with 20% increment was given. The experiment stopped when change in response nature (from positive to negative response, or otherwise) accumulated at five times. \textit{EC}\textsubscript{50} and 95% confidence interval was calculated. \textsuperscript{S3}
SI.4 TEM observations with phosphotungstic acid

General method

The compound was dissolved in pure water with vigorous magnetic stirring (1000 rpm) at 30°C for 12 hours. The solution for TEM observation were prepared by depositing a drop of solution mentioned above onto a 400 mesh copper grid covered with thin amorphous carbon. A drop of phosphotungstic acid (2%) was added for negative staining, which lasted for 5 min. Then the sample would be observed by a Hitachi H-600 TEM (120KV) instrument.\textsuperscript{54}

Each sample was observed for at least twice. For each compound, we began observation from a relative lower concentration (7 mmol/L). If we could not find JPs at this concentration, we would observe this compound at a higher concentration (28 mmol/L except compound 8 and 10). Because nothing could be observed when the sample of compound 8 and 10 was at concentration of 28 mmol/L (the electron beam cannot be transmitted for the sample was too thick), we began observation of these compounds from 14 mmol/L. For each compound, if no JPs was found at two different concentration for twice, we thought this compound could not self-assemble into JPs in this condition, and record the typical images of micelles we observed.

![Figure S17 TEM for Compound 4](image_url)
Figure S18 TEM for Compound 5

Figure S19 TEM for Compound 6

Figure S20 TEM for Compound 7

Figure S21 TEM for Compound 8
Figure S22 TEM for Compound 9

Figure S23 TEM for Compound 10

Figure S24 TEM for Compound 11

Figure S25 TEM for Compound 12
SI.5 TEM observations with other stain agents

General method

Compound 3 was dissolved in pure water with vigorous magnetic stirring (1000 rpm) at 30°C for 12 hours. The solution (7mmol/L) for TEM observation were prepared by depositing a drop of solution mentioned above onto a 400 mesh copper grid covered with thin amorphous carbon. A drop of phosphomolybdic acid (2%) or uranyl acetate (2%) was added for negative staining, which lasted for 5min. Then the sample would be observed by a Hitachi H-600 TEM (120KV) instrument.

![Figure S26 TEM for Compound 3 stained by phosphomolybdic acid](image1)

![Figure S27 TEM for Compound 3 stained by uranyl acetate](image2)

SI.6 DLS measurements

Dynamic light scattering (DLS) measurements were performed with Malvern Zetasizer Nano-ZS90. He-Ne laser with a wavelength of 633nm was used. The temperature was set to 25°C and the scattering angle was fixed at 90°. The results were calculated by number mean. 

Table S4 DLS measurements of compound 3
<table>
<thead>
<tr>
<th>Entry</th>
<th>Conc. (mmol/L)</th>
<th>T(℃)</th>
<th>Number Mean (d.nm)</th>
<th>PdI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>25</td>
<td>48.70</td>
<td>0.223</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>25</td>
<td>32.60</td>
<td>0.263</td>
</tr>
<tr>
<td>3</td>
<td>25</td>
<td>25</td>
<td>39.12</td>
<td>0.334</td>
</tr>
<tr>
<td>4</td>
<td>28</td>
<td>25</td>
<td>51.45</td>
<td>0.368</td>
</tr>
<tr>
<td>5</td>
<td>42</td>
<td>25</td>
<td>77.65</td>
<td>0.390</td>
</tr>
</tbody>
</table>

**Size Distribution by Number**

**7mmol/L**

**Size Distribution by Number**

**14mmol/L**
SI.7 Cryo-TEM observation

The Cryo-TEM samples were prepared in a controlled environment vitrification system (CEVS). The sample solution (4μL) was coated onto a TEM copper grid. The grid was blotted with two pieces of filter paper for about 2 seconds, leading to the

**Figure S28**  Particle size distribution by number mean

- **25mmol/L**
- **28mmol/L**
- **42mmol/L**
formation of a solution thin film. Then the grid was quickly plunged into a reservoir of liquid ethane (-165°C, cooled by liquid nitrogen) and kept in liquid nitrogen until the observation. After transferring the grid to a cryogenic sample holder (Gatan 626) and putting the holder into a JEOL JEM-1400 Plus TEM (120KV) instrument at about -174, we could observe the nanostructure of the sample.56

Without the operation of negative staining by phosphotungstic acid, photographs of spherical micelles were unclear on the concentration of 3.5mmol/L on these experiments. So we began these observations on the concentration of 7mmol/L.

SI.8 Determination of onset time

The in vivo effect of 3 and 8 was investigated on a rat sciatic nerve block model in a blind, randomized and controlled fashion.

![Graph showing onset time vs concentration for compounds 3 and 8](image)

* n = 6–8 (n = 6 at 3.5mM; n = 8 at 7mM). In comparison between 3 and 8 at 3.5mmol/L, p = 0.069.

**Figure S29** Determination of onset time on rat sciatic nerve block model

All animal experimental procedures were approved by Committee of Scientific Research and Institutional Animal Experimental Ethics, West China Hospital, Sichuan University (No. 2015014A). Sprague Dowley rats (Dossy Experimental Animal Company, Chengdu, China) weighted 200~400g were housed at room temperature and moiety of 40%~60%, in 12h light/12h dark cycle with free access to food and water. Animals were acclimated to experimental environments before tests.
During acclimation, baseline of sensory and motor function was measured every day for three consecutive days, averaged, and recorded. Animals with normal baselines were used, and were randomized into groups (n = 6~8 for each group).

Rats received sciatic nerve block under sedation with inhaled 1.5%~2.0% isoflurane (v/v %) mixing with 100% oxygen. 0.2 ml of test solution was injected through a 27-Gauge syringe that was inserted at the mid-point between trochanter and ischial tuberosity. In preliminary experiments, 100% successful rate was obtained with standard peri-sciatic nerve injection procedure common local anesthetics, besides no signs of nerve injury was observed for injection.

Sensation of the injected limb was evaluated after sciatic nerve block by revised hot plate test at 10min, 30min, hourly in 4 hours, every 2 hours within 12 hours, and every 12h thereafter. In revised hot plate test, rats were gently held, the paw of injected limb was placed on a 52°C metal plate. The paw withdrawal latency (PWL) induced by heat stimulation represents the degree of sensation block. The baseline of PWL lasted no longer than 3s, and the cutoff time of PWL was set at 12s to avoid tissue injury. PWL > 7s was considered effective nerve blockade. The time for PWL to exceed 7s was the onset time of sensory block; PWL returned below 7s was the offset of sensory block; the interval between onset and offset time was the duration of nerve blockade.

Systemic adverse effect was inspected during the injection and 5min after injection. To exclude false positive results, only the efficacy lasting for more than 5min was recorded to be onset. Any signs of sedation, convulsion, seizure, ataxia, excitation, or death were recorded. So did local adverse effects including necrosis, sustain paralysis, muscle spasm, self-mutilation, and so forth.

References


S7 Binshtok, A.M.; Gerner P.; Bae, S. *Anesthesiology* 2009, 111, 127-137.
